FibroGen, Inc. (FGEN)
NASDAQ: FGEN · Real-Time Price · USD
0.3138
-0.0062 (-1.94%)
Apr 25, 2025, 4:00 PM EDT - Market closed
FibroGen Revenue
In the year 2024, FibroGen had annual revenue of $29.62M, down -36.71%. FibroGen had revenue of $3.14M in the quarter ending December 31, 2024.
Revenue (ttm)
$29.62M
Revenue Growth
-36.71%
P/S Ratio
1.08
Revenue / Employee
$131,649
Employees
225
Market Cap
31.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 29.62M | -17.18M | -36.71% |
| Dec 31, 2023 | 46.80M | -93.93M | -66.74% |
| Dec 31, 2022 | 140.73M | -94.58M | -40.19% |
| Dec 31, 2021 | 235.31M | 58.99M | 33.46% |
| Dec 31, 2020 | 176.32M | -80.26M | -31.28% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
FGEN News
- 23 days ago - FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 5 weeks ago - FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 7 weeks ago - FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million - Benzinga
- 2 months ago - FibroGen sells China unit to AstraZeneca in deal worth $160 million - Reuters
- 2 months ago - FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million - GlobeNewsWire
- 4 months ago - FibroGen Appoints David DeLucia as Chief Financial Officer - GlobeNewsWire